Best of the Blog: Start-Up February 2008
This article was originally published in Start Up
Best of the Blog is a monthly column highlighting the best of our online content at www.windhover.com/blog. In February, Windhover's staff posted 52 articles to the site, covering biopharma, device and diagnostics R&D, business development, regulatory, and commercial news.
You may also be interested in...
Few drugs have succeeded in accelerating bone and muscle growth because of the complexity of delivering compounds systemically. Acceleron Pharma hopes to overcome these problems with first-in-class agents to release the brakes holding back the endogenous processes that encourage this growth. The approach Acceleron is taking will allow for systemic administration and should produce effects on the entire skeletal system--not just a local effect.
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.